

CA-ADAP Medical Advisory Committee: Formulary Review

JANUARY 20, 2021

KRISTEN M. HALOSKI, PHARM.D.
AAHIVP


MagellanRx
MANAGEMENTSM

CA-ADAP Formulary Review: AGENDA

ADAP's formulary covers antiretroviral treatment, opportunistic infection treatment, and select medications for common comorbidities among people living with HIV

At each MAC meeting several classes of therapeutics will be reviewed. Today's meeting will focus on:

- Agents used in the treatment of Chronic Obstructive Pulmonary Disorder (COPD)
- Anticoagulants




Therapeutic Class Review

COPD TREATMENT

MagellanRx
MANAGEMENTSM

Chronic Obstructive Pulmonary Disease (COPD)^{1,2,3,4}



- ❖ COPD is one of the most common chronic diseases in PLWH⁵
 - As noted at CROI 2019, affecting 15-20% or more of PLWH

➤ Consequences of uncontrolled disease include:

- Rapid decrease in lung function
- Reductions in Quality of Life
- Frequent emergency department (ED), urgent care, medical provider visits, and hospitalizations
- Premature death

❖ Classes of Medications used to treat COPD:

- 1) Inhaled Short-Acting Beta2 Agonists (SABAs)
- 2) Inhaled Short-Acting Antimuscarinic Agent (SAMA)
- 3) Inhaled Long-Acting Beta2 Agonists (LABAs)
- 4) Inhaled Long-Acting Antimuscarinic Agent (LAMA)
- 5) Phosphodiesterase Inhibitors (PDE inhibitors)

COPD Pharmacotherapy



Agent	Generic	CA ADAP FORMULARY
INHALED SHORT-ACTING BETA2-AGONISTS (SABAs)		
Albuterol Inhalers (PROVENTIL, VENTOLIN, PROAIR)	X	
Levalbuterol HFA (XOPENEX)	X	
INHALED SHORT-ACTING ANTIMUSCARINIC AGENT (SAMAs)		
Ipratropium (ATROVENT HFA or solution for nebulization)	X nebulizer solution	
COMBINATION INHALED SAMA/SABA		
Ipratropium/Albuterol (COMBIVENT RESPIMAT, DUONEB solution for nebulization)	X nebulizer solution	
INHALED LONG-ACTING BETA2-AGONISTS (LABAs)		
Salmeterol (SEREVENT DISKUS)		
Formoterol (PERFOROMIST, solution for nebulization)		
Indacaterol (ARCAPTA NEOHALER)		
Olodaterol (STRIVERDI RESPIMAT)		
Arformoterol (BROVANA, solution for nebulization)		
INHALED LONG-ACTING ANTIMUSCARINIC AGENT (LAMAs)		
Tiotropium (SPIRIVA)		
Acclidinium (TUDORZA PRESSAIR)		
Umeclidinium (INCRUSE ELLIPTA)		
Glycopyrrolate (SEEBRI NEOHALER, LONHALA MAGNAIR)		

COPD Pharmacotherapy



Agent	Generic	CA ADAP FORMULARY
COMBINATION INHALED LAMA/LABA		
Aclidinium/Formoterol (DUAKLIR PRESSAIR)		
Glycopyrrolate/Indacaterol (UTIBRON NEOHALER)		
Glycopyrrolate/Formoterol (BEVESPI AEROHALER)		
Tiotropium/Olodaterol (STIOLTO RESPIMAT)		
Umeclidinium/Vilanterol (ANORO ELLIPTA)		
COMBINATION INHALED ICS/LABA		
Budesonide/Formoterol (SYMBICORT)	X	
Fluticasone/Salmeterol (ADVAIR HFA or DISKUS)	X Diskus	
Fluticasone/Vilanterol (BREO ELLIPTA)		
Mometasone/Formoterol (DULERA)*		
COMBINATION ICS/LAMA/LABA		
Fluticasone/Umeclidinium/Vilanterol (TRELEGY ELLIPTA)		
Budesonide/Glycopyrrolate/Formoterol (BREZTRI AEROSPHERE)		

*Off-Label Use

COPD Pharmacotherapy



Agent	Generic	CA ADAP FORMULARY
PHOSPHODIESTERASE INHIBITORS (PDE inhibitors)		
Roflumilast (DALIRESP)		
MACROLIDE ANTIBIOTICS		
Azithromycin (ZITHROMAX)	X	X

A large, irregular blue shape with a white background. The shape is tilted and has several colorful triangles (orange, lime green, purple, magenta, cyan) scattered around it. The text is centered within the blue shape.

Therapeutic Class Review

ANTICOAGULANT THERAPY

MagellanRx
MANAGEMENTSM

Anticoagulant Pharmacotherapy



Agent	Generic	CA ADAP FORMULARY
VITAMIN K ANTAGONISTS		
Warfarin (COUMADIN)	X	
DIRECT THROMBIN INHIBITOR (DTI)		
Dabigatran (Pradaxa)		
DIRECT FACTOR XA INHIBITORS		
Apixaban (ELIQUIS)		
Rivaroxaban (XARELTO)		

References



1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2021 Report. www.goldcopd.org (Accessed December 28, 2020)
2. Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM et al. Pharmacologic management of COPD: an official ATS clinical practice guideline. *Am J Respir Crit Care Med* 2020; 201(9):e56-369. <https://www.atsjournals.org/doi/10.1164/rccm.202003-0625ST> (Accessed December 30, 2020)
3. CDC. <https://www.cdc.gov/copd/basics-about.html> (Accessed January 2, 2021)
4. Venkata, VS, Kieman, G. COVID-19 and COPD: Pooled Analysis of Observational Studies. *CHEST* 2020; 158(4):A2469. <https://doi.org/10.1016/j.chest.2020.09.046>. (Accessed January 2, 2021).
5. Crothers, K., Harding, B.N., Whitney, B.M., et al. COPD and the risk for Myocardial Infarction by type in people living with HIV. Conference of Retroviruses and Opportunistic Infections (CROI 2019). <https://www.croiconference.org/abstract/copd-and-risk-myocardial-infarction-type-people-living-hiv/> (Accessed December 28, 2020)
6. American College of Chest Physicians. Antithrombotic Therapy and Prevention of Thrombosis (9th Edition): February 2012. <https://www.chestnet.org/Guidelines-and-Resources/CHEST-Guideline-Topic-Areas/Pulmonary-Vascular> (Accessed January 3, 2021).
7. American Society of Hematology. American Society of Hematology 2020 guidelines for management of venous thromboembolism; treatment of deep vein thrombosis and pulmonary embolism. *Blood Adv* (2020) 4 (19): 4693–4738. <https://ashpublications.org/bloodadvances/article/4/19/4693/463998/American-Society-of-Hematology-2020-guidelines-for> (Accessed January 3, 2021).
8. Coumadin [package insert]. Princeton, NJ; Bristol-Myers Squibb Company.; August 2017.
9. Pradaxa [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals, Inc.; July 2020.
10. Eliquis [package insert]. Princeton, NJ; Bristol-Myers Squibb Company.; November 2019.
11. Xarelto [package insert]. Titusville, NJ; Janssen Pharmaceuticals, Inc.; March 2020.

Confidentiality statement



By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc.

The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.

The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.